Abstract
Phortress (the dihydrochloride salt of the lysylamide prodrug of 2-(4-amino-3-methylphenyl)-5-fluoro-benzothiazole (5F 203)) is an experimental antitumor agent with potent and selective activity against human-derived carcinomas of breast, ovarian and renal origin. UK clinical trials of Phortress are scheduled to begin in 2004. The mechanism of action of Phortress is distinct from all classes of chemotherapeutic agents currently in the clinic, and involves metabolic activation by cytochrome P450 (CYP) 1A1 to electrophilic species, which generate DNA adducts in sensitive tumors only. In the present study, the antitumor efficacy of Phortress has been compared with that of doxorubicin (Dox) in nine human-derived mammary carcinoma xenograft models, cultivated subcutaneously in the flanks of nude mice. In addition, cyp1a1 mRNA expression was measured in tumors of control and treated animals. Phortress compared favorably with Dox: significant activity, independent of estrogen receptor (ER) status, was established in 7/9 xenografts; in one xenograft model, Phortress elicited superior antitumor activity; no model demonstrated complete resistance to Phortress. In accordance with this observation, all xenografts available for examination ...Continue Reading
References
Jan 1, 1992·Journal of Cancer Research and Clinical Oncology·H NaundorfJ Frege
Oct 1, 1988·Molecular Endocrinology·P J VickersK H Cowan
Nov 1, 1973·Journal of the National Cancer Institute·H D SouleM Brennan
Jan 1, 1994·Breast Cancer Research and Treatment·H NaundorfS Reinecke
Jan 1, 1993·Journal of Cancer Research and Clinical Oncology·H NaundorfB Büttner
Aug 16, 1996·Journal of Medicinal Chemistry·D F ShiM F Stevens
Mar 26, 1998·British Journal of Cancer·T D BradshawM F Stevens
Dec 17, 1998·Carcinogenesis·F G CroftsP T Strickland
Jun 6, 2000·British Journal of Cancer·H NaundorfI Fichtner
Jul 20, 2000·British Journal of Cancer·T D BradshawM F Stevens
Apr 20, 2001·Journal of Medicinal Chemistry·I HutchinsonM F Stevens
Dec 26, 2001·Molecular Pharmacology·Andrea I Loaiza-PérezEdward A Sausville
Jan 25, 2002·Journal of Medicinal Chemistry·Ian HutchinsonMalcolm F G Stevens
Apr 16, 2002·British Journal of Cancer·T D BradshawM F G Stevens
Feb 6, 2003·British Journal of Cancer·C-O LeongM F G Stevens
Feb 28, 2003·Molecular Pharmacology·Anne MonksEdward A Sausville
Citations
Aug 4, 2007·Breast Cancer Research and Treatment·Tracey D BradshawMalcolm F G Stevens
Oct 4, 2012·Journal of Enzyme Inhibition and Medicinal Chemistry·Prabodh Chander SharmaDharam Pal Pathak
Sep 10, 2014·Journal of Enzyme Inhibition and Medicinal Chemistry·Leyla YurttaşSeref Demirayak
Oct 18, 2015·Bioorganic & Medicinal Chemistry·Erica L StoneTracey D Bradshaw
May 23, 2013·Journal of Cellular Biochemistry·Mariana A CalleroAndrea I Loaiza Perez
Aug 16, 2006·Bioorganic & Medicinal Chemistry Letters·Cedric J LionAndrew D Westwell
Jun 25, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ioannis SpyrouVasilis P Androutsopoulos
Feb 9, 2013·Journal of Enzyme Inhibition and Medicinal Chemistry·Leyla YurttaşŞafak Ulusoylar-Yıldırım
Apr 8, 2015·Organic & Biomolecular Chemistry·Patrique NunesAntónio Paulo
Jun 21, 2011·Bioorganic & Medicinal Chemistry·Khalid Mohammed KhanM Iqbal Choudhary
Nov 19, 2015·PloS One·Pantelis StavrinouPeriklis Pappas
Jun 14, 2017·British Journal of Cancer·Hans R HendriksGodefridus J Peters
Jan 13, 2018·Molecular Carcinogenesis·Simon C BakerJennifer Southgate
Dec 8, 2005·Molecular Pharmacology·Anders WallqvistAnne Monks
Aug 13, 2011·Molecular Cancer Therapeutics·Boon Shing TanChee-Onn Leong
Apr 12, 2013·Molecular Cancer Research : MCR·Mariangellys Rodriguez, David A Potter
Aug 1, 2008·Journal of Medicinal Chemistry·Stefania AielloAndrew D Westwell
Jan 6, 2006·Journal of Medicinal Chemistry·Catriona G MortimerAndrew D Westwell
Aug 31, 2021·Journal of Enzyme Inhibition and Medicinal Chemistry·Livio RacanéSilvana Raić-Malić
Jun 23, 2006·Journal of Medicinal Chemistry·David A VasselinMalcolm F G Stevens